authors
- Siu, LL
- Hotte, Sebastien
- Laurie, SA
- Singh, S
- Winquist, E
- Chia, SKL
- Chen, EX
- Chan, KK
- Wang, T
- Taylor, I
- Ruiz-Garcia, A
- Mormont, C
- Soulieres, D
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2011
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal